Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06651593 · ClinicalTrials.gov registry record · Phase 2

Phase II Biomarker Study of SAR444881 in Combination With Cemiplimab in Solid Tumors

A Phase 2 study of Solid Tumors, sponsored by M.D. Anderson Cancer Center.

Recruiting
Registry status
Phase 2
Development phase
40
Enrollment target
1
Study location

NCT06651593: Recruiting Phase 2 study of Solid Tumors, sponsored by M.D. Anderson Cancer Center.

NCT06651593 is a Phase 2 study of Solid Tumors that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 40 participants, below the 284-participant average among 125 other Solid Tumors trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06651593, a Phase 2 study of Solid Tumors, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.

RECRUITING
Registry status
Phase 2
Development phase
40 participants
Enrollment target
1
Study location

Study Summary

To study possible biomarkers that may be related to how SAR444881 works (either alone or when combined with cemiplimab) in participants with solid tumors.

Primary Outcome

Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0

Conditions Studied

Solid Tumors

Interventions

  • DRUG Cemiplimab
  • DRUG SAR444881

Study Locations (1)

Texas

  • Md Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2025-07-02
Est. Completion 2030-09-01
Phase Phase 2
M.D. Anderson Cancer Center

2,692 total trials

What NCT06651593 shows while recruiting

NCT06651593 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 284-participant average among 125 other Solid Tumors trials with a reported enrollment target (86% lower).

The record links to 1 condition, with Solid Tumors appearing as the primary indexed condition, and to 2 interventions - of which Cemiplimab is the first listed.

NCT06651593 reports a single indexed study location in Texas.

Frequently Asked Questions

What is clinical trial NCT06651593 about?

NCT06651593 is a clinical study titled "Phase II Biomarker Study of SAR444881 in Combination With Cemiplimab in Solid Tumors". To study possible biomarkers that may be related to how SAR444881 works (either alone or when combined with cemiplimab) in participants with solid tumors.

What is the current status of trial NCT06651593?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2025-07-02. Estimated completion is 2030-09-01.

What conditions does trial NCT06651593 study?

This clinical trial studies the following conditions: Solid Tumors.

What interventions are being tested in trial NCT06651593?

The interventions under investigation include: Cemiplimab (DRUG), SAR444881 (DRUG).

Who is sponsoring clinical trial NCT06651593?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06651593 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Solid Tumors

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06651593's enrollment target sits among peer trials

40 96th of 125 higher than 26 of 125 other Solid Tumors trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Solid Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01306019 · 40 participants · Phase 1

    Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)

  • NCT01608152 · 40 participants

    Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors

  • NCT01668082 · 40 participants · NA

    An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection

  • NCT02015013 · 40 participants · Phase 2

    Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT06651593

Source: ClinicalTrials.gov NCT06651593, the US trial registry maintained by the National Library of Medicine. NCT06651593 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.